Drug Interaction Report

The desmopressin in Stimate has a major potential interaction with Asthma.

Water intoxication and hyponatremia may occur during therapy with vasopressin or desmopressin due to their antidiuretic action. Patients are most likely to experience this problem if their fluid intake is excessive or if they do not require antidiuresis, such as when they are administered these agents for their hemostatic effects. Fluid intake should be adjusted carefully to avoid overhydration, particularly in children, elderly, and patients with conditions that may be exacerbated by fluid retention, including epilepsy, migraine, asthma, and heart failure. Patients should be monitored for signs of water intoxication (e.g., listlessness, drowsiness, and headaches), which may rarely progress to seizures and coma. The use of desmopressin is contraindicated in patients with hyponatremia or a history of hyponatremia.

The desmopressin in Stimate has a major potential interaction with Fluid Retention.

Water intoxication and hyponatremia may occur during therapy with vasopressin or desmopressin due to their antidiuretic action. Patients are most likely to experience this problem if their fluid intake is excessive or if they do not require antidiuresis, such as when they are administered these agents for their hemostatic effects. Fluid intake should be adjusted carefully to avoid overhydration, particularly in children, elderly, and patients with conditions that may be exacerbated by fluid retention, including epilepsy, migraine, asthma, and heart failure. Patients should be monitored for signs of water intoxication (e.g., listlessness, drowsiness, and headaches), which may rarely progress to seizures and coma. The use of desmopressin is contraindicated in patients with hyponatremia or a history of hyponatremia.

The desmopressin in Stimate has a major potential interaction with Heart Failure.

Water intoxication and hyponatremia may occur during therapy with vasopressin or desmopressin due to their antidiuretic action. Patients are most likely to experience this problem if their fluid intake is excessive or if they do not require antidiuresis, such as when they are administered these agents for their hemostatic effects. Fluid intake should be adjusted carefully to avoid overhydration, particularly in children, elderly, and patients with conditions that may be exacerbated by fluid retention, including epilepsy, migraine, asthma, and heart failure. Patients should be monitored for signs of water intoxication (e.g., listlessness, drowsiness, and headaches), which may rarely progress to seizures and coma. The use of desmopressin is contraindicated in patients with hyponatremia or a history of hyponatremia.

The desmopressin in Stimate has a moderate potential interaction with High Blood Pressure.

The use of desmopressin, primarily in parenteral administration and/or in large doses, has been infrequently associated with changes in blood pressure, causing either slight elevations or transient decreases with a compensatory increase in heart rate. Therapy with desmopressin, regardless of route of administration, should be administered cautiously in patients with coronary artery insufficiency and/or hypertensive cardiovascular disease.

The desmopressin in Stimate has a moderate potential interaction with History, Thrombotic/Thromboembolic Disorder.

Rare cases of thrombotic events (thrombosis, acute cerebrovascular thrombosis, and acute myocardial infarction) have been reported following desmopressin injection in patients predisposed to thrombus formation. Although a causal relationship has not been established, therapy with desmopressin should be administered cautiously in patients with a current or past history of thrombotic or thromboembolic disorders.

The desmopressin in Stimate has a major potential interaction with Hyponatremia.

Water intoxication and hyponatremia may occur during therapy with vasopressin or desmopressin due to their antidiuretic action. Patients are most likely to experience this problem if their fluid intake is excessive or if they do not require antidiuresis, such as when they are administered these agents for their hemostatic effects. Fluid intake should be adjusted carefully to avoid overhydration, particularly in children, elderly, and patients with conditions that may be exacerbated by fluid retention, including epilepsy, migraine, asthma, and heart failure. Patients should be monitored for signs of water intoxication (e.g., listlessness, drowsiness, and headaches), which may rarely progress to seizures and coma. The use of desmopressin is contraindicated in patients with hyponatremia or a history of hyponatremia.

The desmopressin in Stimate has a moderate potential interaction with Ischemic Heart Disease.

The use of desmopressin, primarily in parenteral administration and/or in large doses, has been infrequently associated with changes in blood pressure, causing either slight elevations or transient decreases with a compensatory increase in heart rate. Therapy with desmopressin, regardless of route of administration, should be administered cautiously in patients with coronary artery insufficiency and/or hypertensive cardiovascular disease.

Loratadine has a moderate potential interaction with Liver Disease.

Loratadine is primarily converted by the liver to an active metabolite, and both parent drug and metabolite are excreted in the urine. Patients with renal and/or liver disease may be at greater risk for adverse effects from loratadine due to drug and metabolite accumulation. The manufacturer recommends one-half the regular dosage initially in patients with liver failure or decreased renal function (GFR < 30 mL/min). Due to the differential effects of hepatic impairment on the serum half-life and clearance of loratadine and pseudoephedrine, the use of products containing a fixed combination of these drugs is not recommended in the presence of liver failure.

The desmopressin in Stimate has a major potential interaction with Migraine.

Water intoxication and hyponatremia may occur during therapy with vasopressin or desmopressin due to their antidiuretic action. Patients are most likely to experience this problem if their fluid intake is excessive or if they do not require antidiuresis, such as when they are administered these agents for their hemostatic effects. Fluid intake should be adjusted carefully to avoid overhydration, particularly in children, elderly, and patients with conditions that may be exacerbated by fluid retention, including epilepsy, migraine, asthma, and heart failure. Patients should be monitored for signs of water intoxication (e.g., listlessness, drowsiness, and headaches), which may rarely progress to seizures and coma. The use of desmopressin is contraindicated in patients with hyponatremia or a history of hyponatremia.

The desmopressin in Stimate has a major potential interaction with Renal Dysfunction.

The use of desmopressin is contraindicated in patients with moderate to severe renal impairment (defined as a creatinine clearance below 50 mL/min).

Loratadine has a moderate potential interaction with Renal Dysfunction.

Loratadine is primarily converted by the liver to an active metabolite, and both parent drug and metabolite are excreted in the urine. Patients with renal and/or liver disease may be at greater risk for adverse effects from loratadine due to drug and metabolite accumulation. The manufacturer recommends one-half the regular dosage initially in patients with liver failure or decreased renal function (GFR < 30 mL/min). Due to the differential effects of hepatic impairment on the serum half-life and clearance of loratadine and pseudoephedrine, the use of products containing a fixed combination of these drugs is not recommended in the presence of liver failure.

The desmopressin in Stimate has a major potential interaction with Seizures.

Water intoxication and hyponatremia may occur during therapy with vasopressin or desmopressin due to their antidiuretic action. Patients are most likely to experience this problem if their fluid intake is excessive or if they do not require antidiuresis, such as when they are administered these agents for their hemostatic effects. Fluid intake should be adjusted carefully to avoid overhydration, particularly in children, elderly, and patients with conditions that may be exacerbated by fluid retention, including epilepsy, migraine, asthma, and heart failure. Patients should be monitored for signs of water intoxication (e.g., listlessness, drowsiness, and headaches), which may rarely progress to seizures and coma. The use of desmopressin is contraindicated in patients with hyponatremia or a history of hyponatremia.

The desmopressin in Stimate has a moderate potential interaction with Thrombotic/Thromboembolic Disorder.

Rare cases of thrombotic events (thrombosis, acute cerebrovascular thrombosis, and acute myocardial infarction) have been reported following desmopressin injection in patients predisposed to thrombus formation. Although a causal relationship has not been established, therapy with desmopressin should be administered cautiously in patients with a current or past history of thrombotic or thromboembolic disorders.